Forte Biosciences, Inc.
FBRX
$17.00
$1.338.49%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -73.53% | -95.54% | -51.31% | -18.72% | -36.00% |
| Total Depreciation and Amortization | 62.79% | 64.10% | 57.14% | 71.43% | 138.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 122.03% | 105.01% | 53.55% | 38.78% | 14.41% |
| Change in Net Operating Assets | 51.03% | 606.20% | 86.70% | -117.94% | 611.17% |
| Cash from Operations | -72.32% | -65.50% | -49.55% | -25.88% | -14.13% |
| Capital Expenditure | 40.22% | -213.51% | -539.13% | 2.13% | 2.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | 201.10% | 39,300.00% | -96.10% | 191.85% |
| Cash from Investing | -118.21% | 200.67% | 1,222.73% | -96.98% | 636.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 45.10% | 44.93% | 58,113.45% | 411.70% | 111.91% |
| Repurchase of Common Stock | -20.59% | 17.14% | 44.44% | 56.45% | 55.26% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -49.07% | -563.19% | -3,036.26% | -2,873.53% | -1,163.97% |
| Cash from Financing | 44.84% | 33.75% | 127,709.47% | 385.75% | 100.82% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -19.76% | 467.67% | 358.37% | 1,910.99% | 382.37% |